CLEARBRIDGE Health $ Clearbridge: 1H3 -2.27% on Wednesday said its second batch of Sinopharm Covid-19 vaccines have arrived in Singapore.

 

The vaccines will be available at Medic Surgical & Laser Clinic, operated by the group' s subsidiary, the integrated healthcare group said in a bourse filing.

 

The group' s first batch of Sinopharm vaccines had arrived in Singapore on Aug 28 and were fully allocated in early September.

 

Clearbridge Health said it has also facilitated other healthcare institutions in Singapore to have access to the Sinopharm vaccine. This includes Royal Healthcare Specialists Centre, which will be taking part of this second batch of vaccine shipment under the special access route approved by the Health Sciences Authority.

 

The group said these healthcare institutions have certain reporting obligations to its manufacturer China National Biotec Group (CNBG), such as reporting of adverse events after inoculation.

 

Clearbridge Health' s unit, Clearbridge Medical Group, had earlier entered into a contract to purchase the Sinopharm Covid-19 vaccine directly from its manufacturer, which includes CNBG and Beijing Institute of Biological Product.

 

The Sinopharm Covid-19 vaccine has been authorised for conditional and emergency use in several countries, and is listed by the World Health Organization for emergency use.

 

The group said it aims to procure and supply the Sinopharm vaccine in Singapore and other countries in the region.

 

 

 

 

 

 

SINGAPORE, 22 September 2021 &ndash Asia&rsquo s integrated healthcare company, Clearbridge Health Limited (&ldquo Clearbridge&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ) (" 明 策 集 团 &rdquo ), is pleased to announce that the second batch of SARS-CoV-2 Vaccine (Vero Cell), Inactivated or COVID-19 Vaccine (Vero Cell), Inactivated, also known as COVID-19 Vaccine BIBP (the " Sinopharm COVID-19 Vaccine" ) procured by its subsidiary, Clearbridge Medical Group Pte. Ltd. (&ldquo CBMG&rdquo ), has arrived in Singapore today.

 

The Group&rsquo s first batch of the Sinopharm COVID-19 Vaccine arrived on 28 August 2021 and the Group&rsquo s subsidiary, which operates Medic Surgical & Laser Clinic, was one of the first healthcare institutions to administer the Sinopharm COVID-19 Vaccine in Singapore1. 

 

With its first batch of the Sinopharm COVID-19 Vaccine being fully allocated in early September 2021, the Group had placed another order which has arrived in Singapore today.

 

With its purchase contract with, among others, China National Biotec Group Company Limited (中 国 生 物 技 术 股 份 有 限 公 司 ) (&ldquo CNBG&rdquo ) and Beijing Institute of Biological Product Co., Ltd. (北 京 生 物 制 品 研 究 所 有 限 责 任 公 司 ), a subsidiary of CNBG, to purchase the Sinopharm COVID-19 Vaccine for use in Singapore, the Group has also facilitated other healthcare institutions in Singapore such as the Royal Healthcare Specialists Centre to have access to the Sinopharm COVID-19 Vaccine, where these healthcare institutions have certain reporting obligations to CNBG, including reporting of adverse events after inoculation. Part of this second batch Sinopharm COVID-19 Vaccine shipment is for the Royal Healthcare Specialists Centre, under the Special Access Route approval from the Health Sciences Authority of Singapore.

 

The Sinopharm COVID-19 Vaccine has been authorised for conditional and emergency use in several countries including the People&rsquo s Republic of China, the United Arab Emirates, Malaysia, Thailand and Indonesia. It has also been listed by the World Health Organization for emergency use.

 

As a pan-Asian private healthcare group, Clearbridge has built up a business presence and network across regional markets. 

 

With deep experience and familiarity working with health authorities, medical supply chain logistic partners and healthcare institutions, the Group aims to procure and supply the Sinopharm COVID-19 Vaccine in Singapore and other countries in the region.

 

 

 

 

 

 

&bull Partial early redemption reduces interest payment obligations arising from the convertible bonds

&bull Extension of the maturity date of the remaining convertible bonds to 2024 provides financial flexibility to the Group for expansion of its business

&bull The Group&rsquo s balance sheet remained healthy with total assets increasing from S$96.99 million as at 31 December 2020 to S$100.47 million as at 30 June 2021, of which the Group&rsquo s cash at bank and short-term deposits stood at S$22.28 million

 

SINGAPORE, 17 September 2021 &ndash Asia&rsquo s integrated healthcare company, Clearbridge Health Limited (&ldquo Clearbridge&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ) (" 明 策 集 团 &rdquo ), is pleased to announce that Group will undertake a partial early redemption of S$3,525,000 in principal amount of convertible bonds on a pro rata basis (&ldquo Partial Early Redemption&rdquo ).

 

Following the completion of the Partial Early Redemption, the outstanding principal amount of the convertible bonds will be S$3,525,000.

 

Separately, Clearbridge and the holders of the convertible bonds have entered into an amendment deed to amend certain terms and conditions of the convertible bonds, the key of which was to extend the maturity date of the remaining convertible bonds for a further two years to 8 March 2024 and 17 May 2024, as the case may be, conditional upon completion of the Partial Early Redemption.

 

To pursue acquisitions and business opportunities in Asia&rsquo s healthcare industry, the Group had announced the issuance ofsuch convertible bonds amounting to S$11.0 million in January 2019. Since then, the outstanding principal amount of the convertible bonds has been progressively reduced with an aggregate of S$3.95 million in principal amount of the convertible bonds converted into ordinary shares of the Company in 2020.

 

Mr Jeremy Yee (余 斌 ), Executive Director and Chief Executive Officer of Clearbridge, said, &ldquo The early redemption of the convertible bonds is in line with our prudent capital management strategy, and it also reinforces our commitment to maintain a robust balance

sheet with enhanced financial flexibility.

 

More importantly, there is considerable potential in each of our business segments and the maturity extension reaffirms bondholders&rsquo confidence in our ambitious growth initiatives within Asia&rsquo s healthcare market.&rdquo